5 Most Profitable Biotech Stocks to Buy Now

3. PTC Therapeutics, Inc. (NASDAQ:PTCT)

PTC Therapeutics, Inc. (NASDAQ:PTCT) ranks among the most profitable biotech stocks to buy now. On April 28, PTC Therapeutics, Inc. (NASDAQ:PTCT) announced positive outcomes from a 24-month interim assessment of its PIVOT-HD extension trial, which assessed votoplam for the treatment of Huntington’s disease. The trial found dose-dependent improvements in disease progression in people with Stage 2 Huntington’s disease.

According to the Composite Unified Huntington’s Disease Rating Scale, patients on the 10 mg dose showed a 52% slowdown in disease progression compared to a natural history sample, whilst those on the 5 mg dose exhibited a 28% slowdown.

Meanwhile, on April 9, Raymond James began coverage of PTC Therapeutics, Inc. (NASDAQ:PTCT), with an Outperform rating and a $108 price target. The firm emphasized the introduction of Sephience, which is billed as the first and only Phenylketonuria medication that combines oral dose with phenylalanine management and diet adaptability.

Analyst Tiago Fauth noted that the therapy has merits over traditional standard-of-care therapies for the hereditary condition.

PTC Therapeutics, Inc. (NASDAQ:PTCT) is a global biopharmaceutical company that discovers, develops, and commercializes innovative medicines for rare genetic disorders.